Apyx Medical (NASDAQ:APYX) Releases Earnings Results, Beats Estimates By $0.06 EPS

Apyx Medical (NASDAQ:APYX) released its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06, FiscalAI reports. The business had revenue of $12.49 million for the quarter, compared to the consensus estimate of $10.78 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported strong top-line growth in Q1 — $12.5M total revenue, up 32% year-over-year, driven by a 36% increase in Surgical Aesthetics sales to $10.7M largely from AYON system and consumable handpiece demand.
• Management says AYON is in an early but fast ramp following its Sept 2025 launch, and expects FDA 510(k) clearance for power-assisted liposuction this quarter with a limited early-adopter commercial rollout planned.
• The company raised 2026 revenue guidance to $59M–$60M, projects gross margins of ~62%–63% and capped operating expenses at $45M, reflecting improved profitability trends (Q1 GAAP net loss narrowed vs. prior year).
• International momentum is building after recent approvals (notably South Korea), with initial generator and handpiece demand exceeding expectations and plans to register AYON in major markets over time.
• Despite improvements, Apyx remains unprofitable (Q1 net loss attributable to stockholders was $2.1M), expects OEM revenue to decline year-over-year, and has a stated cash runway through 2027 with $31.1M in cash as of March 31, 2026.

Apyx Medical Stock Performance

APYX traded up $0.64 during trading on Thursday, hitting $3.56. The stock had a trading volume of 761,219 shares, compared to its average volume of 178,440. The firm has a market cap of $148.91 million, a PE ratio of -13.18 and a beta of 1.35. Apyx Medical has a 12 month low of $1.08 and a 12 month high of $4.50. The company has a current ratio of 5.00, a quick ratio of 4.26 and a debt-to-equity ratio of 2.35. The company has a 50 day simple moving average of $3.63 and a 200-day simple moving average of $3.70.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on APYX shares. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a report on Friday, March 27th. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Finally, Craig Hallum raised their price target on shares of Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Apyx Medical has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of APYX. Citadel Advisors LLC bought a new position in Apyx Medical in the 3rd quarter worth $28,000. Osaic Holdings Inc. bought a new position in Apyx Medical in the 2nd quarter worth $50,000. Franklin Resources Inc. bought a new position in Apyx Medical in the 3rd quarter worth $59,000. Hudson Bay Capital Management LP bought a new position in Apyx Medical in the 4th quarter worth $73,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Apyx Medical in the 4th quarter worth $111,000. Institutional investors own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.